Medtronic's Hugo RAS System Debuts in U.S. with First Commercial Surgery at Cleveland Clinic

Event summary

  • Medtronic's Hugo RAS system completed its first U.S. commercial surgery, a robotic-assisted prostatectomy at Cleveland Clinic on February 17, 2026.
  • The system received FDA clearance for urologic procedures in December 2025 following the Expand URO clinical study.
  • Cleveland Clinic, Duke University Hospital, and Atrium Health Wake Forest Baptist are among the first U.S. hospitals to install the Hugo RAS system.
  • Medtronic plans to expand the system's use into gynecologic and general surgery procedures.

The big picture

Medtronic's Hugo RAS system represents a strategic push into the U.S. surgical robotics market, which has seen high adoption rates in urology. The system's modular design and mobile footprint address operating room capacity challenges, positioning it as a flexible alternative to existing solutions. The FDA clearance and initial commercial success at Cleveland Clinic signal potential for broader adoption across surgical specialties.

What we're watching

Adoption Pace
How quickly the Hugo RAS system will gain traction in U.S. hospitals beyond the initial adopters.
Indication Expansion
Whether Medtronic can successfully expand the system's use into gynecologic and general surgery procedures.
Competitive Positioning
The impact of Hugo RAS on Medtronic's market share in surgical robotics against established competitors.